Arlesheim, Switzerland

Marcel Gubler

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Basel, CH (2020)
  • Arlesheim, CH (2008 - 2022)

Company Filing History:


Years Active: 2008-2022

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Marcel Gubler: Innovator in Nephrotoxicity Screening

Introduction

Marcel Gubler is a notable inventor based in Arlesheim, Switzerland. He has made significant contributions to the field of nephrotoxicity screening, holding a total of 5 patents. His work focuses on developing methods to predict the nephrotoxic effects of nucleic acid molecules.

Latest Patents

Gubler's latest patents include innovative in vitro nephrotoxicity screening assays. One of his inventions relates to methods for predicting the in vivo nephrotoxicity of nucleic acid molecules, such as siRNA or antisense oligonucleotides. This method utilizes an in vitro cell-based assay that measures the levels of EGFR as a toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1. Another patent also focuses on predicting the nephrotoxicity of drug substances, specifically nucleic acid molecules, using a similar in vitro cell-based assay that measures extracellular EGF levels as a toxicity biomarker.

Career Highlights

Throughout his career, Gubler has worked with prominent companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. His experience in these organizations has contributed to his expertise in nephrotoxicity screening.

Collaborations

Gubler has collaborated with several professionals in his field, including Annie Moisan and Sabine Sewing. These collaborations have likely enhanced his research and development efforts.

Conclusion

Marcel Gubler is a distinguished inventor whose work in nephrotoxicity screening has the potential to impact drug development significantly. His innovative approaches and collaborations continue to advance the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…